92
Faculty disclosures
Hesse, Swen:
Disclosure: None
Hiroi, Noboru:
Disclosure: None
Holmes, Andrew:
Disclosure: None
Howes, Oliver D.:
Disclosure: Funded by MRC UK
Howland, John:
Disclosure: None
Hyytiä, Petri:
Disclosure: None
Illes, Judy:
Disclosure: None
Inoue, Kazuhide:
Disclosure: None
Javitt, Daniel C:
Disclosure: Supported by NIMH
grant U01 MH074356. The author holds intellectual
property rights for treatment of schizophrenia with
D-serine.
Joel, Daphna:
Disclosure: None
Joyce, Eileen:
Disclosure: None
Kapur, Shitij:
Disclosure: Declaration of Interests: Ge-
netic testing and funding for data collection and analy-
sis personnel were provided by AssureRx Health, Inc.
C. Anthony Altar, Ph.D. is employed by AssureRx
Health, Inc.
Kasper, Siegfried:
Disclosure: Prof. Kasper has re-
ceived grant/research support from Bristol Myers-
Squibb, Eli Lilly, GlaxoSmithKline, Lundbeck, Orga-
non, Sepracor and Servier; he has served as a
consultant or on advisory boards for AstraZeneca,
Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Jans-
sen, Lundbeck, Merck Sharp and Dome (MSD), Novar-
tis, Organon, Pfizer, Schwabe, Sepracor, and Servier;
and he has served on speakers# bureaus for Angelini,
AstraZeneca, Bristol Myers-Squibb, Eli Lilly, Janssen,
Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre,
Schwabe, Sepracor, and Servier.
Kato, Tadafumi:
Disclosure: Dr. Kato received a re-
search grant from Takeda Pharmaceutical Company
Limited and honorarium for lectures, manuscripts, or
consultancy from Kyowa Hakko Kirin Co., Ltd., Eli Lilly
Japan K.K., Otsuka Pharmaceutical Co., Ltd., GlaxoS-
mithKline K.K., Taisho Toyama Pharmaceutical Co.,
Ltd., Dainippon Sumitomo Pharma Co., Ltd., Meiji
Seika Pharma Co., Ltd., Pfizer Japan Inc., Mochida
Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen
Pharmaceutical K.K. and Astellas Pharma Inc.
Kelly, John:
Disclosure: None
Kennedy, James:
Disclosure: Dr Kennedy has re-
ceived honoraria from Novartis, Roche, and Eli Lilly.
He is an unpaid member of the AssureRx Health Inc
scientific advisory board.
Kikuchi, Tetsuro:
Disclosure: None
Kim, Dai-Jin:
Disclosure: None
King, Suzanne:
Disclosure: None
Kobilka, Brian:
Disclosure: There is no financial
conflict of interest.
Lanzenberger, Rupert:
Disclosure: R. Lanzenberger
received travel grants and conference speaker hono-
raria from AstraZeneca, Roche and Lundbeck A/S.
Lee, Jung Suk:
Disclosure: None
Lee, Seung-Hwan:
Disclosure: None
Lee, Tae Young:
Disclosure: None
Lesch, Klaus-Peter:
Disclosure: None
Leweke, F. Markus:
Disclosure: None
Leyton, Marco Rupert:
Disclosure: PJC is a mem-
ber of an advisory board for Lundbeck. GH has a
collaboration with Novartis to produce drugs target-
ing the glutamate system.
Lundkvist, Gabriella:
Disclosure: None
Lyte, Mark:
Disclosure: None
Malhotra, Anil:
Disclosure: None
Manji, Husseini:
Disclosure: Dr. Manji is an employ-
ee of Janssen Pharmaceuticals/Johnson & Johnson
Markou, Athina:
Disclosure: Research contract sup-
port from Bristol-Myers-Squibb, Forest Laboratories
and Astra-Zeneca, and consulting fee from AbbVie,
Germany during the last 3 year.
Maruff, Paul:
Disclosure: None
Mayer, Emeran:
Disclosure: None
McGorry, Patrick:
Disclosure: None
Mechelli, Andrea:
Disclosure: None
Mechoulam, Raphael:
Disclosure: 1. I have no sig-
nificant financial interest or other affiliation with a
funding organization or with a commercial sup-
porter of the session and/or provider of commercial
services. 2. I had a grant from NIH (ended 30 Nov
2013).
Meltzer, Herbert:
Disclosure: Financial disclosure
for Dr. Meltzer-Ownership/Investment Interests-
Suregene, ACADIA, GlaxoSmithKline. Industry activi-
ties (such as speaking, advising, consulting, provid-
ingeducationalprograms)–JanssenPharmaceuticals,
Lundbeck Inc., Sunovion Pharmaceuticals Inc, Dai-
nippon Sumitomo Pharma Co., Ltd, TEVA, BiolineRx,
BI (Boehringer Ingelheim Pharma GmbH & Co. KG,
Envivo, Companion Diagnostics, ACADIA. Grant
Support(in last 3 years)-Bioline Rx,Cephalon, Eli Lilly,
Janssen,Pfizer, Sunovion Novartis, Dainippon Sumi-
tomo, Envivo. NeuroTherapeutics Pharma, Inc, Otsu-
ka, Takeda. Alkermes, Naurex, Inc, Reviva Pharma-
ceuticals, Inc, Astellas Research Institute of America.
Minichiello, Liliana:
Disclosure: None
Mitchell, Philip:
Disclosure: None
Möller, Hans-Jürgen:
Disclosure: Prof. Dr. Möller
has received grants or is a consultant for and on the
speakership bureaus of AstraZeneca, Bristol-Myers
Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Janssen
Cilag, Lundbeck, Merck, Novartis, Organon, Pfizer,
Sanofi-Aventis, Schering-Plough, Schwabe, Sepra-
cor, Servier and Wyeth.
Morilak, David:
Disclosure: This work was support-
ed by grants from the National Institutes of Health
